000179371 001__ 179371
000179371 005__ 20240229145541.0
000179371 0247_ $$2doi$$a10.3389/fimmu.2022.811094
000179371 0247_ $$2pmid$$apmid:35359995
000179371 0247_ $$2pmc$$apmc:PMC8964102
000179371 0247_ $$2altmetric$$aaltmetric:124629520
000179371 037__ $$aDKFZ-2022-00622
000179371 041__ $$aEnglish
000179371 082__ $$a610
000179371 1001_ $$0P:(DE-He78)93b84588571c05b85df1c0916f740e98$$aHasche, Daniel$$b0$$eFirst author$$udkfz
000179371 245__ $$aIsoforms of the Papillomavirus Major Capsid Protein Differ in Their Ability to Block Viral Spread and Tumor Formation.
000179371 260__ $$aLausanne$$bFrontiers Media$$c2022
000179371 3367_ $$2DRIVER$$aarticle
000179371 3367_ $$2DataCite$$aOutput Types/Journal article
000179371 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1649153221_16166
000179371 3367_ $$2BibTeX$$aARTICLE
000179371 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000179371 3367_ $$00$$2EndNote$$aJournal Article
000179371 500__ $$a#EA:F030#LA:F030#
000179371 520__ $$aNotably, the majority of papillomaviruses associated with a high cancer risk have the potential to translate different isoforms of the L1 major capsid protein. In an infection model, the cutaneous Mastomys natalensis papillomavirus (MnPV) circumvents the humoral immune response of its natural host by first expressing a 30 amino acid extended L1 isoform (L1LONG). Although inducing a robust seroconversion, the raised antibodies are not neutralizing in vitro. In contrast, neutralizing antibodies induced by the capsid-forming isoform (L1SHORT) appear delayed by several months. We now provide evidence that, although L1LONG vaccination showed a strong seroconversion, these antibodies were not protective. As a consequence, virus-free animals subsequently infected with MnPV still accumulated high numbers of transcriptionally active viral genomes, ultimately leading to skin tumor formation. In contrast, vaccination with L1SHORT was completely protective. This shows that papillomavirus L1LONG expression is a unique strategy to escape from antiviral immune surveillance.
000179371 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000179371 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000179371 650_7 $$2Other$$aMastomys coucha
000179371 650_7 $$2Other$$aNMSC (non-melanoma skin cancer)
000179371 650_7 $$2Other$$acutaneous papillomaviruses
000179371 650_7 $$2Other$$aimmune escape mechanism
000179371 650_7 $$2Other$$amajor capsid protein (L1)
000179371 650_7 $$2Other$$aneutralizing antibodies
000179371 650_7 $$2Other$$avaccination
000179371 650_7 $$2Other$$aviral infection
000179371 7001_ $$0P:(DE-He78)bc487db59becdf534f61e0fb31bc801d$$aAhmels, Melinda$$b1$$udkfz
000179371 7001_ $$0P:(DE-He78)810ef819c7d86928b119192db5730fc7$$aBraspenning-Wesch, Ilona$$b2$$udkfz
000179371 7001_ $$0P:(DE-He78)fd869847d6731bf306dce72ed1ef343b$$aStephan, Sonja$$b3$$udkfz
000179371 7001_ $$0P:(DE-He78)aa2868b980249801b3207f4fbf65660b$$aCao, Rui$$b4
000179371 7001_ $$0P:(DE-He78)e8868a5fc184fe2e756d7e11ad1ac748$$aSchmidt, Gabriele$$b5$$udkfz
000179371 7001_ $$0P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579$$aMüller, Martin$$b6$$udkfz
000179371 7001_ $$0P:(DE-He78)97f27961503f8b3233697cbad1bbed4e$$aRösl, Frank$$b7$$eLast author$$udkfz
000179371 773__ $$0PERI:(DE-600)2606827-8$$a10.3389/fimmu.2022.811094$$gVol. 13, p. 811094$$p811094$$tFrontiers in immunology$$v13$$x1664-3224$$y2022
000179371 909CO $$ooai:inrepo02.dkfz.de:179371$$pVDB
000179371 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)93b84588571c05b85df1c0916f740e98$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000179371 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bc487db59becdf534f61e0fb31bc801d$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000179371 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)810ef819c7d86928b119192db5730fc7$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000179371 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fd869847d6731bf306dce72ed1ef343b$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000179371 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)aa2868b980249801b3207f4fbf65660b$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000179371 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e8868a5fc184fe2e756d7e11ad1ac748$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000179371 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000179371 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)97f27961503f8b3233697cbad1bbed4e$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000179371 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000179371 9141_ $$y2022
000179371 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-01-29
000179371 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000179371 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000179371 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-29
000179371 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-29
000179371 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT IMMUNOL : 2021$$d2022-11-23
000179371 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-23
000179371 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-23
000179371 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T10:28:02Z
000179371 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T10:28:02Z
000179371 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-11T10:28:02Z
000179371 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-23
000179371 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-23
000179371 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT IMMUNOL : 2021$$d2022-11-23
000179371 9202_ $$0I:(DE-He78)F030-20160331$$kF030$$lF030 Virale Transformationsmechanismen$$x0
000179371 9201_ $$0I:(DE-He78)F030-20160331$$kF030$$lF030 Virale Transformationsmechanismen$$x0
000179371 9201_ $$0I:(DE-He78)W210-20160331$$kW210$$lLichtmikroskopie$$x1
000179371 9201_ $$0I:(DE-He78)F035-20160331$$kF035$$lF035 Tumorvirus-spez. Vakzinierungsstrategie$$x2
000179371 9200_ $$0I:(DE-He78)F030-20160331$$kF030$$lF030 Virale Transformationsmechanismen$$x0
000179371 980__ $$ajournal
000179371 980__ $$aVDB
000179371 980__ $$aI:(DE-He78)F030-20160331
000179371 980__ $$aI:(DE-He78)W210-20160331
000179371 980__ $$aI:(DE-He78)F035-20160331
000179371 980__ $$aUNRESTRICTED